

PERSONAL INFORMATION



Name (First, Last): Antonio, Di Meglio

Institution: Gustave Roussy Cancer Campus

Unit: INSERM U981, Molecular Predictors and New Targets in Oncology

Team: Cancer Survivorship Research Program

Office address: 39 rue Camille Desmoulins, 94805, Villejuif, France

Phone: +33 (0)7 67 00 04 57

E-mail: antonio.di-meglio@gustaveroussy.fr

EDUCATION

PhD	University: Université Paris-Saclay, Doctoral School of Oncology Dissertation: “Health Behaviors And Breast Cancer Survivorship” Committee: Fabrice Andre (Director), Ines Vaz-Luis (Co-director), Gabriella Pravettoni, Matteo Lambertini, Stefan Michiels, Helena Canhao	2021
MD, Oncology	Specialty Training Program: Medical Oncology San Martino University Hospital, Genoa, Italy	2017
MD	University: University of Genoa Medical School, Genoa, Italy Medical Degree, Graduated <i>Summa Cum Laude</i>	2011

PROFESSIONAL APPOINTMENTS

Institution: Gustave Roussy, Villejuif, France Role: Physician-Scientist, Cancer Survivorship Program Lead researcher on predictive analyses of quality of life and long-term treatment-related symptoms in breast cancer using the CANTO cohort (NCT01993498); Medical Director of CANTO since 2025. Supervise and mentor oncology trainees and biostatisticians, while providing clinical care across the breast cancer disease spectrum.	2021-present
Institution: Université Paris-Saclay, Paris, France Role: PhD candidate, Doctoral School of Oncology <i>Supervisor: Ines Vaz-Luis, Fabrice André</i> <i>Thesis: “Health Behaviors and Breast Cancer Survivorship”</i> Multiple projects using CANTO cohort data to investigate the impact of health behaviors on quality of life in breast cancer survivors, informing a phase III randomized trial of weight loss (NCT04304924). PhD included extensive biostatistics and programming work: predictive model development and validation, longitudinal analyses, missing data management, and multimodal data integration.	2018-2020
Institution: Gustave Roussy, Villejuif, France Role: Clinical Research Fellow of the European Society for Medical Oncology (ESMO) <i>Supervisor: Ines Vaz-Luis</i> Mentored fellowship focused on quantitative research methodologies to study health behaviors and long-term treatment toxicity among breast cancer survivors using CANTO cohort data. Recognized with the Best ESMO Fellowship Project Award at ESMO Congress 2019.	2017-2018

Institution: Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, United States 2015-2016

Role: Clinical Research Fellow, Breast Oncology Program

Supervisors: Ines Vaz-Luis, Nancy U. Lin

Mentored fellowship focused on outcomes research and biostatistics. Research included (i) patterns and factors influencing imaging follow-up in women with metastatic breast cancer within a Dana-Farber cohort, and (ii) analysis of SEER population-based data to describe temporal trends in incidence and survival of de novo metastatic breast cancer. Contributed to the design of a clinical trial on G-CSF de-escalation (NCT02698891; PMID: 32330102).

Institution: San Martino University Hospital, Genoa, Italy 2012-2017

Role: Medical Oncology Resident, Medical Oncology residency program

Supervisors: Francesco Boccardo, Mario Roberto Sertoli

Medical oncology training, including clinical residency (internal medicine and oncology). Research work focused on clinical outcomes, management of treatment-related toxicities, and implementation of clinical trials, including participation in breast cancer research networks such as the Italian Breast Cancer Study Group (GIM).

Institution: Temple University, Philadelphia, PA, United States 2011

Role: Lab intern, Fels Institute

Supervisor: Scott K. Shore

Gained laboratory research experience working on the project “*Determination of a role for the non-receptor tyrosine kinase c-Abl in hormone-dependent tumorigenesis.*”

ADDITIONAL TRAINING AND PROFESSIONAL CERTIFICATIONS

Type of training/Certification	Organization/Institution	Year
<u>Supervision Accreditations</u> National Scientific Qualification, Italy	(“Abilitazione Scientifica Nazionale”; https://abilitazione.mur.gov.it/public/index.php)	2023
<u>Leadership and Scientific Communication</u> ESMO Leaders Generation Programme Project Management Course	ESMO Gustave Roussy, Paris, France	2020-2022 2021
<u>Board Certifications and Medical Licences</u> Medical Oncology Medical Oncology	French Medical Council Italian Medical Council	2021 2012
<u>Advanced Research Methodologies</u> European Diploma of Clinical and Translational Research in Oncology 24th Workshop on Methods in Clinical Cancer Research	Université Paris-Saclay, Paris, France EORTC, ESMO, AACR	2018 2024
<u>Biostatistics and Programming</u> Programming with R Longitudinal Data Analysis Fundamentals of Clinical and Translational Research Biostatistics: introductory, intermediate, and advanced module	INSERM Seminars, Paris, France INSERM Seminars, Paris, France Harvard Catalyst Education Program Brigham and Women’s Hospital, Boston, MA	2020 2019 2015-2016 2015

AWARDS AND GRANTS

AWARDS

Faculty Recognition Award at MCCR 2024	2024
ESMO Merit Travel Grant	2024
University of Padua Award for advances in breast cancer	2022
Conquer Cancer Foundation Pain and Symptom Management Special Merit Award at the ASCO Annual Meeting (Highest-ranking abstract according to Scientific Program Committee)	2021
Best ESMO Fellowship Project Award - ESMO Congress	2019
Conquer Cancer Foundation Merit Award - ASCO Annual Meeting	2019
Travel Award - EORTC Quality of Life in Cancer Clinical Trials Conference	2019
Travel Grant - ESMO Preceptorship on Breast Cancer	2019
Merit Award - ESMO Congress	2018
Travel Grant - ESMO IMPAKT Breast Cancer Conference	2017
Travel Grant - ESMO Signaling Pathways	2014
Travel Grant - ESMO Symposium on Immunotherapy of Cancer	2013
IFMSA Research Internship Award - Temple University, Philadelphia, PA, United States	2011
IFMSA Research Internship Award - Hospital de Santa Maria, Lisbon, Portugal	2010
IFMSA Clinical Internship Award - Hospital del Mar, Barcelona, Spain	2009

GRANTS (as Principal or Senior Investigator)

Funding Agency: Conquer Cancer, the ASCO Foundation Young Investigator Award (2023-2024)
Project Title: Informing an optimal Strategy to Manage ARomatase-inhibitor Musculoskeletal Toxicity
Role (Amount): Project Mentor (50,000 \$)

Funding Agency: ARC - French Foundation for Cancer Research (2022-2025)
Project Title: STRATEGY-QOL
Role (Amount): Principal Investigator (449,715 €)

Funding Agency: Maison Sciences de l'Homme et Institut Excellence DataIA (2022-2024)
Project Title: INTERTOx: INTegrated Effort to better understand and communicate the Risk of breast cancer related TOXicities
Role (Amount): Principal Investigator (160,000 €)

Funding Agency: INCa - French National Institute of Cancer (2021-2024)
Project Title: ATTITUDE: ATTRition In longiTUDinal studiEs of cancer survivors
Role (Amount): Principal Investigator (476,928 €)

Funding Agency: Conquer Cancer, the ASCO Foundation and Rising Tide Foundation (2020-2024)
Career Pathway Grant in Symptom Management
Project Title: A comprehensive bio-behavioral approach to tackle cancer-related fatigue in breast cancer survivors.
Role (Amount): Principal Investigator (460,000 \$)

GRANTS (as Co-investigator)

Funding Agency: European Union HORIZON-HLTH-2024-DISEASE-03-two-stage (2025-2031)

Project Title: Personalized Adjuvant Treatment for HR+/HER2- breast cancer for young patients

Role (Amount): Co-investigator (Overall grant: ~9,400,000 €) WP6 leader (« Analyses addressing issues of relevance to premenopausal patients »), WP12-13-14 co-leader (« Project Management »)

Funding Agency: ANR - French National Research Agency (2021-2028)

Project Title: WeShare - Web-based Exploitation of Social and Human sciences to Advance cancer Research: a French research infrastructure for social and human science in cancer research

Role (Amount): Co-investigator (Overall grant: ~11,000,000 €)

Funding Agency: INCa - French National Institute of Cancer (2021-2024)

Project Title: PANDORA - Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOocrine theRApy in patients with early breast cancer

Role (Amount): Co-investigator (Overall grant: ~400,000 €)

Funding Agency: INCa - French National Institute of Cancer (2021-2024)

Project Title: OPERA - Odyssey PERsonalized Approach: mitigation of endocrine therapy side effects with a dedicated pill and web-interface to avoid deterioration of quality of life and improve treatment adherence

Role (Amount): Co-investigator (Overall grant: ~480,000 €)

Funding Agency: INCa - French National Institute of Cancer (2019-2022)

Project Title: MEDEA - Motivating to Exercise and Diet, and Educating to healthy behaviors After breast cancer: a randomized controlled trial of personalized telephone-based intervention to reduce (NCT04304924)

Role (Amount): Co-investigator (Overall grant: ~480,000 €)

FELLOWSHIP GRANTS

Funding Agency: European Society for Medical Oncology (2017-2018)

Project Title: Health Behaviors and Long-term Treatment Toxicity Among Breast Cancer Survivors: A Quantitative Analysis in the French Prospective CANTO Cohort (Grant: 40,000 €; Role: Principal Investigator)

ADDITIONAL EXPERIENCE/PROFESSIONAL DEVELOPMENT

TEACHING AND MENTORSHIP

PhD Students Supervisor, Gustave Roussy - Université Paris-Saclay

- Dr Pietro Lapidari; Project: "Informing an optimal Strategy to Manage ARomatase-inhibitor Musculoskeletal Toxicity" (2023-present). Mentor for the associated ASCO Young Investigator Award.
- Dr Martina Pagliuca: "Clusters of behavioral symptoms after breast cancer" (2022-present)

PhD Committee Advisor, International Advisory Committees

- Viktorya Voskanian; Project: "Breast cancer patients, survivors and decision-making" (2023-present). European School of Molecular Medicine / Istituto Europeo di Oncologia, Milan, Italy - External Advisor.

DUERTECC Research Supervisor, Gustave Roussy- Université Paris-Saclay

- Dr Pedro Cacilhas, Project: "Physical Activity data from wearable devices in the MEDEA randomized clinical trial" (2025-2026)
- Dr Stefano Maccarone, Project: "Dietary patterns in the MEDEA randomized clinical trial" (2024-2025)
- Dr Camila Chiodi; Project: " Attrition in longitudinal studies of cancer survivors" (2022-2023)
- Dr Daniele Presti; Project: " Factors associated with enrolment in clinical trials among women with early-stage breast " (2020-2021)
- Dr Davide Soldato; Project: "Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer" (2020-2021)
- Dr Pietro Lapidari; Project: "Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors" (2019-2020)

Oncology Trainees Thesis Supervisor, Gustave Roussy

- Dr Martina Pagliuca; Project "Mapping biobehavioral symptoms clusters after breast cancer" (2022-)
- Dr Rayan Kabirian; Project: "Factors associated with chemotherapy-related amenorrhea and its relationship with quality of life in premenopausal women with early breast cancer" (2021-2023)
- Dr Youssef Ghanam; Project: "ImPact of Radiotherapy On Fatigue at 1 year in Breast cancer survivors in the prospective multicenter CANTO cohort" (Co-mentor with Dr Sofia Rivera; 2021-2022)
- Dr Daniele Presti; Project: "Cancer-related cognitive impairment (CRCI) in early breast cancer (BC) survivors" (2020-2021)
- Dr Pietro Lapidari; Project: "Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors" (2019-2020)
- Dr Mylene Annonay; Project: "Factors associated with increased Body Mass Index among breast cancer survivors" (2018-2019)

Master Students Supervisor, Gustave Roussy

- Achille Perrot - Master in Biostatistics; Project: "Clonal hematopoiesis and breast cancer outcomes" (2024)
- Ho Hang - Master in Biostatistics; Project: "Investigating sexual health after breast cancer by longitudinal assessment of patient reported outcomes" (2021)
- Engineering students focused on cancer research - École polytechnique, Paris, France; Project: "Social and environmental determinants of cancer-related fatigue in breast cancer survivors"

Other mentorship activities

- Alec Stear – Medical student/Biostatistics; Project: "Proteomic analyses in CANTO" (2025)
- Mentor for the ESMO Mentorship program 2024-2025
- Mentor for the ESO Mentorship program 2025-2026

Other lectures and seminars given

- **Clinical/Research Seminars at Gustave Roussy**, covering the following topics: health behaviors and cancer, breast cancer survivorship, symptom management (since 2017)
- Served as expert or discussant for the **European School of Oncology (ESO) e-sessions** (since 2018)
- Faculty, ESO Masterclass in Clinical Oncology - Summer edition 2024 and 2025 Block 1
- Faculty, 25th EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research

PARTICIPATION IN INTERNATIONAL EXPERT WORKING GROUPS AND COLLABORATIVE PROJECTS

- Member of the **ESMO Public Policy Committee** (2023-2024, first mandate; 2025-2026, second mandate)
- Expert for the **European Educational Program on Unmet needs in HER2+ metastatic breast cancer, initiated by the ESMO Young Oncologist Committee** (since 2023)
- Survivorship Expert for the **pan-European initiative to UNDERstand CANcer (UNCAN.eu) of the Mission on Cancer Board and European Beating Cancer Plan** (since 2022)
- Expert for the **Implementation Network Europe for Cancer Survivorship Care (INE-CSC) of the European Cooperation in Science and Technology (COST Action CA21152)** (since 2022)
 - WG 2: Implementation of digital solutions to support cancer survivorship care
 - WG 3: Implementation of science theory-based framework & toolkit to support cancer survivorship care
 - WG 4: Capacity building, dissemination and sustainability

PROFESSIONAL SERVICES

Editorial roles

- **Leading Guest Editor**, European Journal of Cancer Care - Cancer related fatigue Issue (2023-2024)
- **Editorial Board Member**, BMC Cancer (Since 2024)
- **Academic Editor**, European Journal of Cancer Care (Since 2024)

Manuscript reviewer for the following peer-reviewed and indexed journals (since 2015):

- | | |
|--|--|
| • ASCO Educational Book | • Scientific Reports |
| • Journal of the National Cancer Institute | • Current Oncology |
| • British Journal of Cancer | • Frontiers in Oncology |
| • JCO Oncology Practice | • European Journal of Clinical Investigation |
| • European Journal of Cancer | • ecancermedalscience |
| • Oncotarget | • Forum of Clinical Oncology |
| • Cancers | • American Journal of Hematology/Oncology |
| • Cancer Medicine | • Integrative Cancer Therapies |
| • Critical Reviews in Oncology/Hematology | • Supportive Care in Cancer |
| • Breast Cancer Research and Treatment | |

Reviewer for academic research grants

- **World Cancer Research Fund** | Investigator Initiated Grant Full 2023 - United Kingdom
- **SHAPE-Med@Lyon** | Structuring projects 2023 - France
- **KWF Dutch Cancer Society** | 2024 -2 DEV call / Young Investigator Grant - Netherlands
- **World Cancer Research Fund** | Investigator Initiated Grant Full 2024 - United Kingdom
- **Deutsche Forschungsgemeinschaft** | German Research Foundation Clinical Trials Programme 2025 – Germany

PUBLICATIONS

Peer-reviewed Journal Publications (From most recent)

1. **Risk models of cancer related cognitive complaints among early breast cancer survivors in the CANTO cohort.** Presti D, **Di Meglio A**, Havas J, Pagliuca M, Cheaib B, Martin AL, Gaudin C, Jouannaud C, Fournier M, Kieffer A, Campone M, Lerebours F, Petit T, Boyault S, Bertaut A, Tredan O, Cherifi F, Lange M, Pradon C, Vaz-Luis I, Joly F. *J Natl Cancer Inst* 2025 PMID: 40900676.
2. **Identifying Patients with Low Relapse Rate Despite High-Risk ER+/HER2- Early Breast Cancer: Development and Validation of a Clinicopathological Assay.** Bidard FC, Gessain G, Bachelot T, Frechin L, Vincent-Salomon A, Drubay D, Lemonnier J, Walter T, Penault-Llorca F, Martin AL, Gaudin C, Bichat A, Sassi F, Berlemont S, Chavez-MacGregor M, Rugo HS, Badoual C, Pistilli B, Ribeiro J, **Di Meglio A**, Lacroix-Triki M, Vaz Luis I, Lerusseau M, André F. *J Clin Oncol* 2025 PMID: 40845255.
3. **Safety of having a subsequent pregnancy after prior diagnosis of breast cancer during pregnancy in young BRCA carriers.** Perachino M, Blondeaux E, Delucchi V, Bernstein Molho R, Frank S, Paluch-Shimon S, Linn S, Peccatori F, Moore HCF, Parokonnaya A, Renaud T, Rodriguez Wallberg KA, Partridge AH, Pogoda K, Ferrari A, Wildiers H, Toss A, Rousset-Jablonski C, Kim HJ, Varela M, Cordoba O, Tanase Damian C, Marhold M, Fabi A, Graff SL, Rodriguez-Hernandez A, Okano M, Duchnowska R, Luna Pais H, Di Rocco R, Azim HA Jr, Mariamidze E, Kourie HR, Arecco L, Carrasco E, Agostinetto E, Balmana J, Saura C, Lambertini M. *ESMO Open*. 2025 PMID: 40811881.
4. **Breastfeeding after breast cancer in young BRCA carriers.** Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Jeong Kim H, Agostinetto E, Paluch-Shimon S, Cortesi L, **Di Meglio A**, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, Bianchini G, Teixeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA Jr, Peccatori FA, Partridge AH, Lambertini M. *J Natl Cancer Inst* 2025 PMID: 4062300
5. **"Let's talk about risk": co-designing a pathway to assess, communicate and act on individual risk of long-term toxicities after breast cancer.** Franzoi MA, Santolaya C, Martin E, Fasse L, Rouby P, Minot-This MS, **Di Meglio A**, Vaz-Luis I. *J Cancer Surviv* 2025 PMID: 40504480
6. **Protocol for an umbrella review of systematic reviews evaluating the efficacy of digital health solutions in supporting adult cancer survivorship care.** Keane D, Calbimonte JP, Pawłowska E, Kassianos AP, Medina JC, Gregório J, Serra-Blasco M, Celebic A, **Di Meglio A**, Asadi-Azarbaijani B, Foster C, Donohoe CL, Mafra A, Backes C, Ochoa-Arnedo C, Gezer D, Bozkul G, Horata ET, Özkan E, Prue G, İçsan G, Dural G, Bahçecioğlu G, Ersöğütçü F, Bêrziņa G, Bektas H, Vaz-Luis I, Mlakar I, Rocha-Gomes J, O'Connor M, Clara MI, Karekla M, Hagen MH, İmançer MS, Çöme O, Mevsim V, Aksoy N, Martins RM, Yokuş SE, Bayram SB, Can AA, Brandão T, Saab MM, Muluk NB, Yıldırım Z, Podina IR, Karadağ S, Erden S, Semerci R, Aydın A, Frountzas M, Cura ŞÜ, Ruveyde A, Billis A, Calleja-Agius J, Vojvodic K, Jaswal P, Sahin E, Ilgaz A, Pilleron S, Hegarty J. *PLoS One* 2025 PMID: 40424277
7. **Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.** Daucchia C, Alice Franzoi M, Martel S, Agbor-Tarh D, Fielding S, Piccart M, Bines J, Loibl S, Di Cosimo S, Vaz-Luis I, **Di Meglio A**, Del Mastro L, Gombos A, Desmedt C, Jerusalem G, Reaby L, Pienkowski T, Lambertini M, Agostinetto E, Azambuja E; APHINITY Steering Committee and Investigators. *Eur J Cancer* 2025 PMID: 40367619
8. **Interaction between APOE ε4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.** Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, **Di Meglio A**, Ganz PA, Van Dyk K, Vaz Luis I, Lange M, Joly F. *Breast Cancer Res*. 2025 PMID: 39972319.
9. **Experiences and preferences about information on treatment-related side effects among patients with early breast cancer.** **Di Meglio A**, Catanuto G, Zambon M, Chan A, Kassianos AP, Cloconi C, Rohr S, Steele R, Coersmeyer M, Ujupan S, Peccatori F. *Breast*. 2025 PMID: 39947086.

10. **Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study.** Jourdain H, Di Meglio A, Mansouri I, Desplas D, Zureik M, Haddy N. *ESMO Open*. 2024 PMID: 39662227.
11. **Precision oncology in patients with breast cancer: towards a 'screen and characterize' approach.** Rassy E, Mosele MF, Di Meglio A, Pistilli B, Andre F. *ESMO Open* 2024 PMID: 39303452.
12. **Reply to S. Yang.** Soldato D, Vaz-Luis I, Di Meglio A, Jones LW, Michiels S. *J Clin Oncol* 2024 PMID: 39303199.
13. **Long-term behavioral symptom clusters among survivors of early-stage breast cancer. development and validation of a predictive model.** Pagliuca M, Havas J, Thomas E, Drouet Y, Soldato D, Francoi MA, Ribeiro J, Chiodi CK, Gillanders E, Pistilli B, Menvielle G, Joly F, Lerebours F, Rigal O, Petit T, Giacchetti S, Dalenc F, Wassermann J, Arsene O, Martin AL, Everhard S, Tredan O, Boyault S, De Laurentiis M, Viari A, Deleuze JF, Bertaut A, André F, Vaz-Luis I, Di Meglio A. *J Natl Cancer Inst* 2024 PMID: 39250750.
14. **Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study.** Francoi MA, Pages A, Papageorgiou L, Di Meglio A, Laparra A, Martin E, Barbier A, Renvoise N, Arvis J, Scotte F, Vaz-Luis I. *JMIR Res Protoc* 2024 PMID: 39186774.
15. **A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later.** Di Meglio A, Havas J, Pagliuca M, Francoi M A, Soldato D, Chiodi C K, Gillanders E, Dubuisson F, Camara-Clayette V, Pistilli B, Ribeiro J, Joly F, Cottu P H, Tredan O, Bertaut A, Ganz P A, Bower J, Partridge A H, Martin A L, Everhard S, Boyault S, Brutin S, André F, Michiels S, Pradon C, Vaz-Luis I. *Ann Oncol* 2024 PMID: 39098454
16. **Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers.** Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetti E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, Graff SL, Witzel I, Rodriguez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M. *Ann Oncol* 2024 PMID: 38908482.
17. **Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort.** Sandoval JL, Francoi MA, Di Meglio A, Ferreira AR, Viansone A, André F, Martin AL, Everhard S, Jouannaud C, Fournier M, Rouanet P, Vanlemmens L, Dhaini-Merimeche A, Sauterey B, Cottu P, Levy C, Stringhini S, Guessous I, Vaz-Luis I, Menvielle G. *J Clin Oncol* 2024 PMID: 38889372.
18. **Breast cancer survivors' opinion on personalizing endocrine therapy and developing informative tools.** Rassy E, Benvenuti C, Akla S, Di Meglio A, Martin E, Havas J, Rieutord A, Combarel D, Fasse L, Scotté F, Guéroult Accolas L, Jacob G, Bergougnoux A, Delalogue S, Vaz-Luis I, Pistilli B. *NPJ Breast Cancer* 2024 PMID: 38886406.
19. **Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.** Duivon M, Lequesne J, Di Meglio A, Pradon C, Vaz-Luis I, Martin AL, Everhard S, Broutin S, Rigal O, Bousrih C, Lévy C, Lerebours F, Lange M, Joly F. *Breast Cancer Res* 2024 Jun PMID: 38840166.
20. **Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer.** Soldato D, Michiels S, Havas J, Di Meglio A, Pagliuca M, Francoi MA, Pistilli B, Iyengar NM, Cottu P, Lerebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, André F, Vaz-Luis I, Jones LW. *J Clin Oncol* 2024 PMID: 38838281.
21. **Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System.** Jourdain H, Mansouri I, Di Meglio A, Zureik M, Haddy N. *ESMO Real World Data and Digital Oncology* 2024 ([https://www.esmorwd.org/article/S2949-8201\(24\)00023-7/fulltext](https://www.esmorwd.org/article/S2949-8201(24)00023-7/fulltext))
22. **Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.** Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, Bernstein Molho R, Linn SC, Pogoda K, Carrasco E, Punie K, Agostinetti E, Lopetegui-Lia N, Phillips KA, Toss A, Rousset-Jablonski C, Acheritogaray M, Ferrari A, Paluch-Shimon S, Fruscio

- R, Cui W, Wong SM, Vernieri C, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Vasconcelos de Matos L, Mariño M, Teixeira L, Graffeo R, Rognone A, Chirco A, Antone N, Abdou Y, Marhold M, Božović-Spasojević I, Cortés Salgado A, Carmisciano L, Bruzzone M, Curigliano G, Prat A, Lambertini M. **Cancer** 2024 PMID: 38752572.
23. **An effort to improve the collection of patient-generated data: readability and understandability of patient-reported outcomes measures in a survivorship cohort.** Chiodi C, Epstein J, Arvis J, Martin E, Barbier A, **Di Meglio A**, Gillanders E, Jacob G, Menvielle G, Everhard S, Guillemin F, Luis IV, Franzoi MA. **Qual Life Res** 2024 PMID: 38441716
 24. **Patient-Reported Quality of Life 6 Years After Breast Cancer.** Franzoi MA, **Di Meglio A**, Michiels S, Gillanders E, Gaudin C, Martin AL, Vaz-Luis I. **JAMA Netw Open** 2024 PMID: 38421653
 25. **Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.** Franzoi MA, Aupomerol M, Havas J, Soldato D, Lambertini M, Massarotti C, Hang H, Pistilli B, Fasse L, Tredan O, Gillanders E, Joly F, Cottu P, Mouret-Reynier MA, Tarpin C, Arnaud A, Everhard S, Martin AL, **Di Meglio A**, Vaz-Luis I. **ESMO Open** 2024 PMID: 38350335
 26. **Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine.** **Di Meglio A**, Vaz-Luis I. **ESMO Open** 2024 PMID: 38194879
 27. **Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.** Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, **Di Meglio A**, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. **JAMA** 2024 PMID: 38059899
 28. **Chemotherapy-related amenorrhea and quality of life among premenopausal women with breast cancer.** Kabirian R, Franzoi MA, Havas J, Coutant C, Tredan O, Levy C, Cottu P, Dhaini Merimece A, Guillermet S, Ferrero JM, Giacchetti S, Petit T, Dalenc F, Rouanet P, Everhard S, Martin AL, Pistilli B, Lambertini M, Vaz-Luis I, **Di Meglio A**. **JAMA Netw Open** 2023 PMID: 37971739
 29. **Sustainable return to work among breast cancer survivors.** Ruiz de Azua G, Kousignian I, Vaz-Luis I, **Di Meglio A**, Caumette E, Havas J, Martin E, Martin AL, Querel O, Vanlemmens L, Pistilli B, Coutant C, Cottu PH, Merimeche AD, Lerebours F, Tredan O, Jouannaud C, Levy C, Dumas A, Menvielle G. **Cancer Med** 2023 PMID: 37602836
 30. **Implementing a PROACTIVE Care Pathway to Empower and Support Survivors of Breast Cancer.** Franzoi MA, Degoussée L, Martin E, Semedo PM, Aupomerol M, Soldato D, **Di Meglio A**, Chiodi C, Barbier A, Chaouachi H, Renvoisé N, Boinon D, Fasse L, Ribeiro J, Le-Provost JB, Arvis J, Lazorthes C, di Palma M, de Jesus A, Raynard B, Pagès A, Delalogue S, Pistilli B, Scotté F, Vaz-Luis I. **JCO Oncol Pract**. 2023 PMID: 37307673
 31. **The Future of Breast Cancer Research in the Survivorship Field.** Soldato D, Arecco L, Agostinetto E, Franzoi MA, Mariamidze E, Begijanashvili S, Brunetti N, Spinaci S, Solinas C, Vaz-Luis I, **Di Meglio A**, Lambertini M. **Oncol Ther**. 2023 PMID: 37005952
 32. **Facing points of view: Representations on adjuvant endocrine therapy of premenopausal patients after breast cancer and their healthcare providers in France. The FOR-AD study.** Roche N, Le Provost JB, Borinelli-Franzoi MA, Boinon D, Martin E, Menvielle G, Dumas A, Rivera S, Conversano A, Matias M, Viansone A, **Di Meglio A**, Delalogue S, Vaz-Luis I, Pistilli B, Fasse L. **Eur J Oncol Nurs**. 2023 PMID: 36623339
 33. **Impact of Radiotherapy On Fatigue at 1 year in Breast cancer survivors in the prospective multicenter CANTO cohort.** Ghannam Y, **Di Meglio A**, Sarrade T, Jacquet A, Everhard S, Kirova Y, Peignaux L, Guilbert P, Chara-Brunaud C, Blanchecotte J, Crehange G, Pasquier D, Racadot S, Bourgier C, Geffrelot J, Benyoucef A, Paris F, Auzac G, Vaz-Luis I, Rivera S. **Eur J Cancer** 2022 PMID: 36356418
 34. **Perceived discrimination at work: examining social, health and work-related factors as determinants among breast cancer survivors – evidence from the prospective CANTO cohort.** Ruiz De Azua G, Vaz-Luis

- I, Bovagnet T, [Di Meglio A](#), Havas J, Caumette E, Martin E, Pistilli B, Coutant C, Cottu P, Rouanet P, Arnaud A, Arsene O, Ibrahim M, Wassermann J, Rouzier R, Martin AL, Everhard S, Dumas A, Menvielle G. *BMJ JECH* 2022
35. **Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study.** Martin E, [Di Meglio A](#), Menvielle G, Arvis J, Bourmaud A, Michiels S, Pistilli B, Vaz-Luis I, Dumas A. *Support Care Cancer* 2022 PMID: 35819520
 36. **Contraceptive Use in Premenopausal Women With Early Breast Cancer.** Lambertini M, Massarotti C, Havas J, Pistilli B, Martin AL, Jacquet A, Coutant C, Coussy F, MÉRIMÈCHE AD, Lerebours F, Rousset-Jablonski C, Jouannaud C, Rigal O, Fournier M, Soulie P, Franzoi MA, Del Mastro L, Partridge AH, André F, Vaz-Luis I, [Di Meglio A](#). *JAMA Netw Open* 2022 PMID: 36149651
 37. **Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review.** Presti D, Dall'Olio FG, Besse B, Ribeiro JM, [Di Meglio A](#), Soldato D. *Crit Rev Oncol Hematol* 2022 PMID: 35917885
 38. **Factors associated with enrolment in clinical trials among women with early-stage breast cancer.** Presti D, Havas J, Soldato D, Lapidari P, Martin E, Pistilli B, Jouannaud C, Emile G, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Campone M, Guillermet S, Martin AL, Everhard S, [Di Meglio A](#). *ESMO Open* 2022 PMID: 35724624
 39. **Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer.** Soldato D, Havas J, Crane TE, Presti D, Lapidari P, Rassy N, Pistilli B, Martin E, Del Mastro L, Martin AL, Jacquet A, Coutant C, Cottu P, Merimeche A, Lerebours F, Tredan O, Vanlemmens L, Andre F, Vaz-Luis I, [Di Meglio A](#). *Cancer* 2022 PMID: 35913436
 40. **Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.** Baker JL, [Di Meglio A](#), Gbenou AS, El Mouhebb M, Iyengar NM, Michiels S, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz-Luis I, Jones LW. *Br J Cancer* 2022 PMID: 35715631
 41. **Dynamics of Long-term Patient-reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy: A Group-based Trajectory Analysis.** [Di Meglio A](#), Havas J, Gbenou AS, Martin E, El-Mouhebb M, Pistilli B, Menvielle G, Dumas A, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Joly F, Delalogue S, Ganz PA, André F, Partridge AH, Jones LW, Michiels S, Vaz-Luis I. *J Clin Oncol* 2022 PMID: 35446677
 42. **Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study.** Aupomerol M, Chaltiel D, Pautier P, Wehrer D, Véron L, Degousée L, Fasse L, Guérault-Accolas L, [Di Meglio A](#), Scotté F, De-Jesus A, Vaz-Luis I, Delalogue S, Lambertini M, Pistilli B. *Cancer Invest* 2022 PMID: 35468006
 43. **Change in the value of work after breast cancer: evidence from a prospective cohort.** Caumette E, [Di Meglio A](#), Vaz-Luis I, Charles C, Havas J, de Azua GR, Martin E, Vanlemmens L, Delalogue S, Everhard S, Martin AL, Merimeche AD, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Cottu PH, Tredan O, Menvielle G, Dumas A. *J Cancer Surv* 2022 PMID: 35267143
 44. **Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France.** Charles C, Bardet A, Larive S, Gorwood P, Ramoz N, Thomas E, Viari A, Rousseau-Tsangaris M, Dumas A, Menvielle M, Everhard E, Martin AL, Gbenou AS, Havas J, El-Mouhebb M, [Di Meglio A](#), Andre F, Vaz-Luis I, Michiels S, Dauchy S. *JAMA Network Open* 2022 PMID: 35420663
 45. **A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA study design.** [Di Meglio A](#), Martin E, Crane TE, Charles C, Barbier A, Raynard B, Mangin A, Tredan O, Bouleuc C, Cottu PH, Vanlemmens L, Segura-Djezzar C, Lesur A, Pistilli B, Joly F, Ginsbourger T, Coquet B, Pauporte I, Jacob G, Sirven A, Bonastre J, Ligibel JA, Michiels S, Vaz-Luis I. *Trials* 2022 PMID: 35246219
 46. **Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.** Vaz-Luis I, [Di Meglio A](#), Havas J, El-Mouhebb M, Lapidari P, Presti D, Soldato D, Pistilli B,

- Dumas A, Menvielle A, Charles A, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Dauchy A, Delalogue S, Lin NI, Ganz PA, Partridge AH, André F, Michiels S. *J Clin Oncol* 2022 PMID: 35290073
47. **Development and validation of a predictive model of severe fatigue after breast cancer: towards a personalized framework in survivorship care.** Di Meglio A, Havas J, Soldato D, Presti D, Martin E, Pistilli B, Menvielle G, Dumas A, Charles C, Everhard S, Martin AL, Coutant C, Tarpin C, Vanlemmens L, Levy C, Rigal O, Delalogue S, Lin NU, Ganz PA, Partridge AH, André F, Michiels S, Vaz-Luis I. *J Clin Oncol* 2022 PMID: 35061509
 48. **Uptake of recommendations for post-treatment cancer-related fatigue among breast cancer survivors.** Di Meglio A, Charles C, Martin E, Havas J, Gbenou A, Flaysakier JD, Martin AL, Everhard S, Laas E, Chopin N, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Soulie P, Scotte F, Pistilli B, Dumas A, Menvielle G, André F, Michiels S, Dauchy S, Vaz-Luis I. *J Natl Compr Canc Netw* 2022 PMID: 35130491
 49. **Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.** Condorelli M, Bruzzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Córdoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Pérez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameys L, Balmaña J, Partridge AH, Azim HA, Demeestere I, Lambertini M. *ESMO Open*. 2021 PMID: 34775302
 50. **The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO Cohort.** Caumette E, Vaz-Luis I, Pinto S, Havas J, Bovagnet T, Ruiz de Azua G, Di Meglio A, Martin AL, Everhard S, Cottu P, Vanlemmens L, Jouannaud C, Lerebours F, Dumas A, Menvielle G. *Curr Oncol*. 2021 PMID: 34677248
 51. **Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.** Lapidari P, Djehal N, Havas J, Gbenou A, Martin E, Charles C, Dauchy S, Pistilli B, Cadeau C, Bertaut A, Everhard S, Martin AL, Coutant C, Cottu P, Menvielle G, Dumas A, Andre F, Michiels S, Vaz-Luis I, Di Meglio A. *Breast Cancer Res Treat*. 2021 PMID: 34559354
 52. **Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.** Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU. *Oncologist*. 2021 PMID: 34472667
 53. **Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy.** Di Meglio A, Soldato D, Presti D, Vaz-Luis I. *Curr Opin Oncol*. 2021 PMID: 34456250
 54. **Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.** Vaz-Luis I, Francis PA, Di Meglio A, Stearns V. *Am Soc Clin Oncol Educ Book*. 2021 PMID: 33989019
 55. **Unhealthy behaviors after breast cancer: capitalizing on a teachable moment to promote lifestyle improvements.** Di Meglio A, Gbenou AS, Martin E, Pistilli B, Ligibel J, Crane T, Flaysakier JD, Menvielle E, Vanlemmens L, Guenancia C, Rigal O, Fournier M, Soulie P, Mouret-Reynier MA, Tarpin C, Boiffard F, Guillermet S, Everhard S, Martin AL, Giacchetti S, Petit T, Dalenc F, Rouanet F, Arnaud A, Andre F, Vaz-Luis I. *Cancer*. 2021 PMID: 33887074
 56. **Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration.** Martin E, Di Meglio A, Charles C, Ferreira A, Gbenou A, Blond M, Fagnou B, Arvis J, Pistilli B, Saghatchian M, Vaz Luis I. *JMIR Cancer*. 2021 PMID: 33749606
 57. **Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer.** Lapidari P, Gbenou A, Havas J, Martin E, Pistilli B, Martin AL, Everhard S, Coutant C, Cottu P, Lesur A, Lerebours F, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Andre F, Vaz-Luis I, Di Meglio A. *Breast*. 2021 PMID: 33711699
 58. **Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.** Lambertini M, Ceppi M, Hamy AS, Caron O, Poorvu PD, Carrasco E, Grinshpun A, Punie K, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Toss A, Senechal C, Puglisi F, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Duhoux FP, Graffeo R, Teixeira

- L, Córdoba O, Sonnenblick A, Ferreira AR, Partridge AH, [Di Meglio A](#), Saule C, Peccatori FA, Bruzzone M, t'Kint de Roodenbeke MD, Ameye L, Balmaña J, Del Mastro L, Azim HA Jr. *NPJ Breast Cancer*. 2021 PMID: 33579978
59. **QualFatigue study: which factors influence the use of specific interventions for breast cancer survivors with fatigue? A cross-sectional exploratory study.** Charles C, [Di Meglio A](#), Arnedos M, Arvis J, Baciarello G, Blanchard P, Djehal N, Dumas A, Hollbecque A, Martin E, Matias M, Menvielle G, Zingarello A, Dauchy S, Vaz-Luis I. *Support Care Cancer*. 2021 PMID: 33547524
 60. **Prediction of Breast Cancer Treatment-Induced Fatigue by Machine Learning Using Genome-Wide Association Data.** Lee S, Deasy JO, Oh JH, [Di Meglio A](#), Dumas A, Menvielle G, Charles C, Boyault S, Rousseau M, Besse C, Thomas E, Boland A, Cottu P, Tredan O, Levy C, Martin AL, Everhard S, Ganz PA, Partridge AH, Michiels S, Deleuze JF, Andre F, Vaz-Luis I. *JNCI Cancer Spectr*. 2020 PMID: 33490863
 61. **Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review.** Lapidari P, Vaz-Luis I, [Di Meglio A](#). *Crit Rev Oncol Hematol*. 2021 PMID: 33309891
 62. **A qualitative evaluation of the use of interventions to treat fatigue among cancer survivors: A healthcare provider's view.** Martin E, Zingarello A, [Di Meglio A](#), Baciarello G, Matias M, Charles C, Arvis J, Dumas A, Menvielle G, Vaz-Luis I. *Eur J Cancer Care (Engl)*. 2020 PMID: 33191520
 63. **Body weight and return to work among survivors of early-stage breast cancer.** [Di Meglio A](#), Menvielle G, Dumas A, Gbenou A, Pinto S, Bovagnet T, Martin E, Ferreira AR, Vanlemmens L, Arsene O, Ibrahim M, Wassermann J, Martin AL, Lemonnier J, Del Mastro L, Jones LW, Partridge AH, Ligibel JA, Andre F, Michiels S, Vaz Luis I. *ESMO Open*. 2020 PMID: 33172957
 64. **Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.** Pistilli B, Paci A, Ferreira AR, [Di Meglio A](#), Poinsignon V, Bardet A, Menvielle G, Dumas A, Pinto S, Dauchy S, Fasse L, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Arveux P, Martin AL, Dima A, Lin NU, Partridge AH, Delalogue S, Michiels S, André F, Vaz-Luis I. *J Clin Oncol*. 2020 PMID: 32568632
 65. **Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.** Zanardi E*, [Di Meglio A](#)*, Boccardo C, Zinoli L, Salvi S, Rubagotti A. *Oncol Res Treat*. 2020 PMID: 32512573 (*Co-first authors)
 66. **Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study.** [Di Meglio A](#), Michiels S, Jones LW, El-Mouhebb M, Ferreira AR, Martin E, Matias M, Lohmann AE, Joly F, Vanlemmens L, Everhard S, Martin AL, Lemonnier J, Arveux P, Cottu PH, Coutant C, Del Mastro L, Partridge AH, André F, Ligibel JA, Vaz-Luis I. *Breast*. 2020 PMID: 32344296
 67. **Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study.** Vaz-Luis I, Barroso-Sousa R, [Di Meglio A](#), Hu J, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, O'Neil K, Partridge A, Burstein H, Waks AG, Trippa L, Tolaney SM, Hassett M, Winer EP, Lin NU. *J Clin Oncol*. 2020 PMID: 32330102
 68. **Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.** Kaboré EG, Guenancia C, Vaz-Luis I, [Di Meglio A](#), Pistilli B, Coutant C, Cottu P, Lesur A, Petit T, Dalenc F, Rouanet P, Arnaud A, Arsene O, Ibrahim M, Wassermann J, Boileau-Jolimoy G, Martin AL, Lemonnier J, André F, Arveux P. *PLoS Med*. 2019 PMID: 31869400
 69. **Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).** Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, [Di Meglio A](#), Pinto S, Charles C, Dauchy S, Delalogue S, Arveux P, Coutant C, Cottu P, Lesur A, Lerebours F, Tredan O, Vanlemmens L, Levy C, Lemonnier J, Mesleard C, Andre F, Menvielle G. *J Clin Oncol*. 2020 PMID: 31834818
 70. **Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors.** Joly F, Lange M, Dos Santos M, Vaz-Luis I, [Di Meglio A](#). *Cancers (Basel)*. 2019 PMID: 31795208
 71. **Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis.** Ferreira AR, [Di Meglio A](#), Pistilli B, Gbenou AS, El-Mouhebb

- M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delalogue S, Michiels S, Andre F, Vaz-Luis I. *Ann Oncol*. 2019 31591636
72. **Fatigue and physical activity in cancer survivors: A cross-sectional population-based study.** Matias M, Baciarello G, Neji M, **Di Meglio A**, Michiels S, Partridge AH, Bendiane MK, Fizazi K, Ducreux M, Andre F, Vaz-Luis I. *Cancer Med*. 2019 PMID: 30864301
 73. **Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.** Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, **Di Meglio A**, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F. *Ther Adv Med Oncol*. 2018 PMID: 29383035
 74. **Targeting androgen-independent pathways: new chances for patients with prostate cancer?** Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, **Di Meglio A**, Fabbroni C, Latocca MM, Rizzo F, Messina C, Rubagotti A, Barboro P, Boccardo F. *Crit Rev Oncol Hematol*. 2017 PMID: 28917268
 75. **Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.** Lambertini M, Ferreira AR, **Di Meglio A**, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. *Clin Breast Cancer*. 2017 PMID: 28479052
 76. **Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.** **Di Meglio A**, Lin NU, Freedman RA, Barry WT, Winer EP, Vaz-Luis I. *J Natl Compr Canc Netw*. 2017 PMID: 28275032
 77. **Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.** **Di Meglio A**, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. *Breast Cancer Res Treat*. 2016 PMID: 27271765
 78. **Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa).** Nuzzo PV, Rubagotti A, Argellati F, **Di Meglio A**, Zanardi E, (...), Boccardo F. *Int J Mol Sci*. 2015 PMID: 26225965
 79. **Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.** Messina C, **Di Meglio A**, Nuzzo PV, Boccardo F, Ricci F. *Tumori*. 2015 PMID: 26045116
 80. **Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature.** **Di Meglio A**, Nuzzo PV, Ricci F, Spina B, Boccardo F. *BMC Cancer*. 2014 PMID: 25159097

Book Chapters

- **Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.** Vaz-Luis I, Francis PA, **Di Meglio A**, Stearns V. *Am Soc Clin Oncol Educ Book* 2021 PMID: 33989019
- **Impact of Systemic Anticancer Therapy on Fertility.** **Di Meglio A**, Vaz-Luis I, Pistilli B, in "Fertility Challenges and Solutions in Women with Cancer". *Springer Nature Switzerland* 2020. ISBN 978-3-030-24085-1

Selected conference abstracts (First or senior author)

- **Systemic inflammation, unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC).** **Di Meglio A** et al. *Mini Oral Presentation, ESMO Congress 2024*
- **Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).** **Di Meglio A** et al. *Oral Presentation, ASCO 2024*
- **Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC).** **Di Meglio A** et al. *Poster Display, ESMO Breast 2024*
- **Germline or acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC).** **Di Meglio A** et al. *Poster Display, SABCS 2023*
- **ATTITUDE - ATTrition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?** Chiodi CK, **Di Meglio A** (senior author). *Poster Display, ESMO 2023*

- Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC). Pagliuca M., **Di Meglio A** (senior author). *Poster Display, ASCO 2023*
- Factors associated with chemotherapy-related amenorrhea and its relationship with quality of life in premenopausal women with early breast cancer. Kabirian R, **Di Meglio A** (senior author). *Oral, ESMO Congress 2022*
- Development of a clinico-bio-behavioral model for cancer-related fatigue (CRF) incorporating inflammatory biomarkers and proteomic data. **Di Meglio A** et al. *Poster Display, SABCS 2021*
- Assessing the risk of severe post-treatment (tx) cancer-related fatigue (CRF) among breast cancer survivors (BCS) in the CANcer TOxicity (CANTO) cohort. **Di Meglio A** et al. *Poster Discussion, ASCO 2021*
- ATTITUDE: understanding and reducing ATTrition In longiTUDinal studiEs of cancer survivors. Lapidari P, **Di Meglio A** (senior author). *Poster Display, SABCS 2021*
- MEDEA: A randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients. **Di Meglio A** et al. *Poster Display, SABCS 2020*
- Long-term patient reported outcomes (PRO) and hematologic toxicity among patients (pts) who received Granulocyte-Colony Stimulating Factors (G-CSF) during chemotherapy (CT) for early breast cancer (EBC). Lapidari P, **Di Meglio A** (senior author) *Mini Oral, ESMO Congress 2020*
- Use Of Physical Activity (PA) And Supportive Care (SC) Among Patients (pts) With Early Breast Cancer (BC) Reporting Cancer-Related Fatigue (CRF). **Di Meglio A** et al. *Oral Presentation, ESMO Breast 2020*
- Lifestyle changes after breast cancer: A prospective study among 8580 women. **Di Meglio A** et al. *Poster Display, SABCS 2019*
- Impact of overweight, obesity, and post-treatment weight changes on occupational reintegration of breast cancer (BC) survivors. **Di Meglio A**, et al. *Poster Display, ASCO Annual Meeting, 2019; recipient of Merit Award*
- Physical Activity (PA) and patterns of Quality of Life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC). **Di Meglio A** et al. - *Poster Discussion, ESMO Congress 2018; recipient of Merit Award; selected for the ESMO Press programme*
- Overweight, obesity and weight gain after breast cancer (BC): a prospective clinical study. **Di Meglio A** et al. - *Poster Display, ESMO Congress 2018; recipient of Merit Award*
- Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). **Di Meglio A**, et al. - *Poster Display, ESMO Congress, 2018*
- Patterns of utilization of imaging and tumor markers among metastatic breast cancer patients. **Di Meglio A** et al. - *ASCO Annual Meeting, 2016*
- Time trends in incidence rates and survival for women with de novo metastatic lobular vs. ductal carcinoma: a population-based study. **Di Meglio A** et al. - *Poster Display, San Antonio Breast Cancer Symposium, 2015*
- Anti-EGFR inhibition for pancreatic cancer. **Di Meglio A** et al. - *Poster Display, 8th Portuguese Oncology Units Congress, 2010*

CONFERENCE PRESENTATIONS AND INVITED LECTURES

<u>Event</u>	<u>Place, Year</u>	<u>Role</u>
• European Breast Cancer Conference (EBCC-15)	Barcelona, Spain 2026	Step leader - "Rehabilitation/Survivorship" Invited Speaker
• Serbian Medical Society 62 th Oncology Congress	Belgrade, Serbia, 2025	Invited Speaker
• ESMO Congress 2025	Berlin, Germany	Invited Speaker
• Moving Beyond scientific conference	Lisbon, Portugal 2024	Invited Speaker
• Integrative Therapies And Women's Cancers	Rome, Italy 2024	Invited Speaker

CURRICULUM VITAE - ANTONIO DI MEGLIO, MD, PHD

• Cured & Chronic Conference	Siracusa, Italy 2024	Invited Speaker
• EORTC Patient Days	Brussels, Belgium 2024	Invited Speaker
• Invasive Lobular Carcinoma (ILC) Symposium	Leuven, Belgium 2024	Invited Speaker
• ESO Masterclass in Clinical Oncology	Online, 2025	Invited Lecturer
• ASCO Annual Meeting	Chicago, IL 2024	Chair, Metastatic Breast Cancer Oral Abstract Session
• ASCO Annual Meeting	Chicago, IL 2024	Oral Presenter
• ESO Masterclass in Clinical Oncology	Online, 2024	Invited Lecturer
• Europa Donna Educational Event (EBCC-14)	Milan, Italy 2024	Invited Speaker
• European Breast Cancer Conference (EBCC-14)	Milan, Italy 2024	Invited Speaker Discussant
• Serbian Medical Society 60 th Oncology Congress	Belgrade, Serbia, 2023	Invited Speaker
• Research Seminars at Policlinico San Martino	Genova, Italy, 2023	Invited Speaker
• Young Breast Oncologists 2 nd edition	Genova, Italy, 2023	Invited Speaker
• Annual Meeting of The Hellenic Society of Medical Oncology (HeSMO)	Athens, Greece, 2023	Invited Speaker Mentorship session
• National GOIRC Congress 2023: “New challenges in academic clinical research”	Bologna, Italy, 2023	Invited Speaker, <i>lectio magistralis</i>
• Returning from San Antonio: Italian Association for Medical Oncology (AIOM)	Online webinar, 2023	Invited Speaker
• Real World Oncology Data at the Sheba Medical Center	Tel Aviv, Israel, 2022	Invited Speaker
• Online seminar of Cancer Education Center and Center for Clinical Epidemiology of the Samsung Cancer Center	Seoul, South Korea, 2022	Invited Speaker
• Breast cancer survivorship: modern needs and future perspectives. Challenges in young patients	Tbilisi, Georgia, 2022	Invited Speaker
• 18th Meet The Professor. Advanced International Breast Cancer Course (AIBCC)	Padova, Italy, 2022	Invited Speaker University of Padua Award
• ESMO Congress	Paris, France, 2022	Session Chair and Discussant
• ESMO Breast Cancer Congress	Berlin, Germany, 2022	Invited Speaker Educational Session
• GRASP Annual Congress	Online, 2021	Invited Speaker
• ESMO Congress	Barcelona, Spain, 2019	Invited Speaker Best ESMO Project
• ESMO Preceptorship on Breast Cancer	Lisbon, Portugal, 2018	Invited Presenter
• Breast Oncology Seminar Series of Dana-Farber/Harvard Cancer Center	Boston, MA, 2015-2016	Invited Speaker
• Research Seminars at Policlinico San Martino	Genoa, Italy 2016-2017	Invited Speaker
• Portuguese Society of Oncology Annual Congress	Aveiro, Portugal 2017	Invited Speaker Educational Session

PROFESSIONAL AFFILIATIONS

European Society for Medical Oncology (ESMO) - Member since 2012
Italian Association of Medical Oncology (AIOM) - Member since 2012
American Society of Medical Oncology (ASCO) - Member since 2015

LANGUAGES

Italian: Native Language
English: Distinguished (Listening, Speaking, Reading, and Writing)
French: Advanced (Listening, Speaking, Reading, and Writing)

COMPUTER SKILLS

Programming: Statistical programming: SAS Environment (Advanced); R Environment (Intermediate)
Applications: Microsoft Office package: Word, Excel, Power Point; Microsoft Outlook
Platforms: Microsoft Windows environment

OTHER

- **Citizenship:** Italian
- **Extra curricula Interests/Hobbies worth noting:** dance; choreography; yoga; biking; cooking
- **Twitter Handle:** @dimeglio_anto

DATE

September 9th, 2025

SIGNATURE


